Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than once
drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses
high-energy x-rays to kill cancer cells. It is not yet known whether giving clofarabine or
high-dose cytarabine, pegaspargase, and combination chemotherapy followed by daunorubicin
hydrochloride or doxorubicin hydrochloride is more effective in treating young patients with
acute lymphoblastic leukemia.
PURPOSE: This randomized phase II/III trial is studying the side effects of giving
clofarabine compared with giving high-dose cytarabine, pegaspargase, and combination
chemotherapy followed by daunorubicin hydrochloride or doxorubicin hydrochloride and to see
how well it works in treating young patients with T-cell acute lymphoblastic leukemia or
precursor B-cell acute lymphoblastic leukemia.